1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Primary Dysmenorrhea - Pipeline Review, H1 2014

Primary Dysmenorrhea - Pipeline Review, H1 2014

  • January 2014
  • -
  • Global Markets Direct
  • -
  • 39 pages

Primary Dysmenorrhea - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, 'Primary Dysmenorrhea - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Dysmenorrhea.
- A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Dysmenorrhea pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Primary Dysmenorrhea - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Dysmenorrhea Overview 6
Therapeutics Development 7
Pipeline Products for Primary Dysmenorrhea - Overview 7
Pipeline Products for Primary Dysmenorrhea - Comparative Analysis 8
Primary Dysmenorrhea - Therapeutics under Development by Companies 9
Primary Dysmenorrhea - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Primary Dysmenorrhea - Products under Development by Companies 12
Primary Dysmenorrhea - Companies Involved in Therapeutics Development 13
Merck and Co., Inc. 13
PDC Biotech GmbH 14
Jiangsu Kanion Pharmaceutical Co., Ltd. 15
Primary Dysmenorrhea - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
KYG-0395 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
etonogestrel Vaginal Ring - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PDC-31 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Peptidometics - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PDC-41 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Primary Dysmenorrhea - Recent Pipeline Updates 32
Primary Dysmenorrhea - Dormant Projects 33
Primary Dysmenorrhea - Product Development Milestones 34
Featured News and Press Releases 34
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 34
Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx 34
Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea 35
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 35
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 35
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 36
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 36
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007. 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables

Number of Products under Development for Primary Dysmenorrhea, H1 2014 7
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Primary Dysmenorrhea - Pipeline by Merck and Co., Inc., H1 2014 13
Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H1 2014 14
Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 18
Number of Products by Stage and Mechanism of Action, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 22
Number of Products by Stage and Molecule Type, H1 2014 24
Number of Products by Stage and Therapeutic Class, H1 2014 26
Primary Dysmenorrhea Therapeutics - Recent Pipeline Updates, H1 2014 32
Primary Dysmenorrhea - Dormant Projects, H1 2014 33

List of Figures

Number of Products under Development for Primary Dysmenorrhea, H1 2014 7
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Target, H1 2014 17
Number of Products by Stage and Top 10 Target, H1 2014 18
Number of Products by Top 10 Mechanism of Action, H1 2014 19
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 20
Number of Products by Top 10 Route of Administration, H1 2014 21
Number of Products by Stage and Top 10 Route of Administration, H1 2014 22
Number of Products by Top 10 Molecule Type, H1 2014 23
Number of Products by Stage and Top 10 Molecule Type, H1 2014 24
Number of Products by Top 10 Therapeutic Class, H1 2014 25
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

Dysmenorrhea  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dysmenorrhea - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Migraine - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

North America Pet Nutraceuticals Market

North America Pet Nutraceuticals Market

  • $ 3850
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The total North American Pet Nutraceuticals market is valued at over $1528.4 million in 2015 and is projected to reach over $XX million by 2020 growing at a CAGR of XX% between the years 2015 and 2020. ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.